Table 61-5: Normal Physical Assessment of the Musculoskeletal System, p Table 61-1: Gerontologic Assessment Differences, p1451

Index. Note: Page numbers of article titles are in boldface type.

Index Note: Page numbers of article titles are in boldface type. A Abatacept, for rheumatoid arthritis, 789 Acetaminophen, for low back pain, 735 Acupuncture for fibromyalgia, 753 for low back pain, 738

Introduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis

Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?

Salicylates: Interactions 10/14/2009. Salicylates DRUGS USED IN THE MANAGEMENT OF MUSCULOSKELETAL DISORDERS. Chapters 17, 18, 34 & Pages 577 &

DRUGS USED IN THE MANAGEMENT OF MUSCULOSKELETAL DISORDERS Chapters 17, 18, 34 & Pages 577 & 579-586 Salicylates aspirin Have analgesic, antipyretic, and anti-inflammatory effects. Inhibits the production

Name: Birthdate: / / LAST FIRST MIDDLE mm dd yyyy. Address: STREET CITY APT # STATE ZIP. Name of Person Making Referral:

Patient History Form Date of first appointment: / / mm dd yyyy Time of appointment: Birthplace: Name: Birthdate: / / LAST FIRST MIDDLE mm dd yyyy Age: Sex: F M Telephone: (H) (C) (W) Address: STREET CITY

CIMZIA (certolizumab pegol)

Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance

Immune Modulating Drugs Prior Authorization Request Form

Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

Patient History Form

Patient History Form of first appointment: / / Time of appointment: Cell Phone: MONTH DA Y YEAR Name: Birthdate: / / LAST FIRST MIDDLE INITIAL MAIDEN MONTH DAY YEAR Address: Age: Sex: F M STREET APT# CITY

RHEUMATOLOGY ASSOCIATES

RHEUMATOLOGY ASSOCIATES Patient History Form Date of first appointment: / / Time of appointment: Birthplace: MONTH DA Y YEAR Name: Birthdate: / / LAST FIRST MIDDLE INITIAL MAIDEN MONTH DAY YEAR Address:

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz

Cimzia. Cimzia (certolizumab pegol) Description

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review

Birthdate: / / Address: Age: Sex: M F. Telephone: H ( ) City State Zip W ( ) C ( )

Please complete this questionnaire in its entirety, even if you feel some questions may not apply to you. Our staff is available should you have any questions, or need assistance with the completion of

New Patient History Form Today s Date:

New Patient History Form Today s Date: MICHAEL L. MAWBY, MD MARIANNE PEACOCK, CNP 1115 S. Union Street Traverse City, MI 49684 Form Revised 1/18/2016 Name: Birthdate: (Last) (First) (MI) (Maiden) (MM/DD/YYYY)

First Name. Specialty: Fax. First Name DOB: Duration:

Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

10 Musculoskeletal and Joint Diseases

10 Musculoskeletal and Joint Diseases To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and British Society of Rheumatology guidelines and guidance

Coverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication

BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi

Otezla. Otezla (apremilast) Description

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background

Index. Note: Page numbers of article titles are in boldface type.

Index Note: Page numbers of article titles are in boldface type. A Abatacept, 239 Acetaminophen, 194 Acupuncture, 205 Adalimumab, 187, 226, 239, 247 Allopurinol, for gout, 188 American College of Rheumatology,

Rheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011

Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease

RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center

RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases

Arthritis. that affects the joints.

Arthritis that affects the joints. The word arthritis literally means inflammation of the joints. Though joint inflammation is often a symptom, rather than a specific diagnosis itself, the term arthritis

Patient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour

Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling

Stelara. Stelara (ustekinumab) Description

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara

Car a e e o f o th f e th e Pati Pa e ti n e t n wi w th i th a Mus u c s u c l u o l s o k s e k l e e l t e al a l Dis i o s r o de d r

Care of the Patient with a Musculoskeletal Disorder 1 Slide 1 Overview of Anatomy and Physiology Function of the bones Support Protection Movement Mineral storage Hemopoiesis Slide 2 Functions of the muscles

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

Cosentyx. Cosentyx (secukinumab) Description

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx

Helpline No:

ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 DRUGS AND ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our

2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients

2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,

Step Therapy Approval Criteria

Effective Date: 10/01/2016 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Cymbalta (duloxetine) 3. Dovonex (calcipotriene) 4. Enbrel (etanercept)

Rheumatoid Arthritis

Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of

Rheumatology Review Update in Internal Medicine COPYRIGHT. Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center.

Rheumatology Review Update in Internal Medicine Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center Boston MA Case #1 True statement(s) regarding etanercept and leflunomide, for the treatment

Corporate Medical Policy

Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and

HAQ-II(Health Assessment Questionnaire-II)

Kathy Karamlou, MD 355 Placentia Ave, suite 208 Newport Beach, CA 92663 949-631-6500 949-631-9700 NAME: DATE: DOB: HAQ-II(Health Assessment Questionnaire-II) We are interested in learning how your illness

Analgesics. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine The University of Jordan March, 2014

Analgesics Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine The University of Jordan March, 2014 Mar-14 Munir Gharaibeh, MD, PhD, MHPE 2 Feature Comparison of Analgesics Narcotic (Opioids) Nonnarcotic

ACTEMRA (tocilizumab)

Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced

2017 Medicare STARs Provider Quality Indicators Guide

2017 Medicare STARs Provider Quality Indicators Guide Medicare STARs Rating Centers for Medicare & Medicaid Services (CMS) created a Five-Star Quality Rating System to help measure the quality in care

Chapter 10 Musculoskeletal and Joint Diseases

Chapter 10 page number 1 First line drugs Drugs recommended in both primary and secondary care Chapter 10 Musculoskeletal and Joint Diseases Second line drugs Alternatives (often in specific conditions)

Pain or stiffness in joints after periods of inactivity or excessive use

Arthritis Awareness* Some older adults call it Arthur ; others refer to it as their constant compassion, but most describe it as extremely painful Arthritis is a chronic joint disease It is commonly believed

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013

Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,

H: Orthopedic Nursing

H: Orthopedic Nursing Alberta Licensed Practical Nurses Competency Profile 87 Competency: H-1 Knowledge of H-1-1 H-1-2 H-1-3 H-1-4 H-1-5 Demonstrate knowledge of human anatomy and physiology, specifically

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown

Medical-Surgical Nursing Care Second Edition Karen Burke Priscilla LeMone Elaine Mohn-Brown Chapter 43 Caring for Clients with Musculoskeletal Disorders Scoliosis Diagnosed in adolescence More common in

Rheumatology Updates for the Primary Care Provider

Rheumatology Updates for the Primary Care Provider Jean Tayar, MD, RhMSUS Associate Professor Section of Rheumatology and Clinical Immunology Department of General Internal Medicine UT MD Anderson Cancer

Biologics for Autoimmune Diseases

Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines

Osteoarthritis. Rheumatology Update. Gout 1/17/2013

Osteoarthritis Rheumatology Update Richard Zweig, MD January, 2013 Degeneration of cartilage over time accompanied by increase in bone density and bone formation around the joint Risks include: aging,

Autoimmune Diseases: Systemic and Oral Health Considerations. Ann Eshenaur Spolarich, RDH, PhD

COURSE TITLE: COURSE INSTRUCTOR: COURSE CREDITS: Autoimmune Diseases: Systemic and Oral Health Considerations JoAnn R. Gurenlian, RDH, PhD and Ann Eshenaur Spolarich, RDH, PhD 2 CEUs COURSE DATE: August

PROVIDER GUIDE Required information on targeted HEDIS and Part D measures

PROVIDER GUIDE Required information on targeted HEDIS and Part D measures Visit www.atriohp.com/star-ratings-program for full measure descriptions. Contact QI@atriohp.com with any questions. Adult Body

Medications Guide June 2017

s Guide June 2017 Arthritis Consumer Experts (ACE) produces its annual JointHealth Medications Guide to enable members/patients-at-large to have a meaningful conversation with their rheumatologist and

Prior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD

Abatacept (Orencia) 1, 2, 7, 11, 13, 14, 18, 24, 31, 44, 48, 49, 51, 53, 55, 57 J0129 Alpha 1 - Proteinase inhibitor (Prolastin-C) 5, 6, 10, 12, 40 Medically Necessary (if all the following criteria apply):

HEALTHCARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS )

STARS MEASURES 2015 HEALTHCARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS ) Developed by the National Committee for Quality Assurance (NCQA), HEDIS is the most widely used set of performance measures

DIAGNOSIS CODING ESSENTIALS FOR LONG-TERM CARE: CHAPTER 13, M CODES MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE

DIAGNOSIS CODING ESSENTIALS FOR LONG-TERM CARE: CHAPTER 13, M CODES MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE Preferred Clinical Services for Leading Age Florida August 26-27, 2015 MUSCULOSKELETAL FUNCTIONS

Infliximab/Infliximab-dyyb DRUG.00002

Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio

Patient History Form Date of first appointment: / / Time of appointment: Birthplace: mm dd yyyy Name: Birthdate: / / LAST FIRST MIDDLE MAIDEN mm dd yyyy Address: STREET APT# Age: Sex: F M Telephone: H

The NOF & NBHA Quality Improvement Registry

In collaboration with CECity The NOF & NBHA Quality Improvement Registry This registry is approved by CMS as a Qualified Clinical Data Registry (QCDR) for Eligible Professionals and GPRO Practices for

Spondyloarthropathies: Disease Perception Limits Market

Spondyloarthropathies: Disease Perception Limits Market Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form

Therapeutic Agents for the Musculoskeletal System

1 Therapeutic Agents for the Musculoskeletal System Chapter 17 1 Anatomy and Physiology of the Skeletal System Provides structural support for the body Consists of muscles, tendons, ligaments, and bones

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Generic Brand HICL GCN Exception/Other GOLIMUMAB SIMPONI 22533, 22536, 34697, 35001 ROUTE = SUBCUTANE. GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a

Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition

Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition Firestein, G ISBN-13: 9781437717389 Table of Contents VOLUME I STRUCTURE AND FUNCTION OF BONE,

Seronegative Arthritis. Dr Mary Gayed 25 th April 2018

Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions

Simponi / Simponi ARIA (golimumab)

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi

MUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed

MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and

Pain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain

Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers

Managing Gout A Review of the Research for Adults

Managing Gout A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional* has said that you have gout. You are age 18 or

What Is Back Pain? Fast Facts: An Easy-to-Read Series of Publications for the Public. Who Gets Back Pain? What Are the Causes of Back Pain?

Back pain can range from a dull, constant ache to a sudden, sharp pain that makes it hard to move. It can start quickly if you fall or lift something too heavy, or it can get worse slowly. Who Gets Back

Proposed Retirement for HEDIS : Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)

Proposed Retirement for HEDIS 1 2020 2 : Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) NCQA seeks public comment on the proposed retirement of the Disease-Modifying Anti-Rheumatic

Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS

Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS Introduction: There is perhaps no rheumatic disease that evokes so much fear and confusion among both patients

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)

Learning Objectives and Assessment Methodologies Combined Medicine-Pediatrics Rheumatology Elective

Learning Objectives and Assessment Methodologies Combined Medicine-Pediatrics Rheumatology Elective Overview: Med-Peds PGY2 s, PGY3 s and PGY4 s can elect to spend one four-week rotation with the adult

Rheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations. Heather Hansen, MD

Rheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations Heather Hansen, MD Objectives Know Broad Categories of Rheumatoid Arthritis Medications

Rheumatoid Arthritis

Rheumatoid Arthritis Rheumatoid Arthritis (RA) is a form of arthritis characterized by swelling and pain in the joints. If severe enough RA can also affect people s internal organs. RA is considered an

Managing Osteoarthritis Pain With Medicines. A Review of the Research for Adults

Managing Osteoarthritis Pain With Medicines A Review of the Research for Adults Is This Summary Right for Me? Yes, if: A doctor* said you have osteoarthritis (pronounced ah-stee-oharth-rye-tis). Osteoarthritis

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade

Corporate Medical Policy

Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a

Available Strengths. Cost per Rx 325 mg tablet - $ mg tablet - $ mg ER tablet - $ mg capsule - $ mg chewable tablet

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Non-Opioids LAST REVIEW 5/9/2017 THERAPEUTIC CLASS Pain REVIEW HISTORY 2/16, 5/15 LOB AFFECTED Medi-Cal (MONTH/YEAR) This

BENEFIT CHANGES TO NBPDP

Bulletin #789 June 15, 2010 BENEFIT CHANGES TO NBPDP This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective June 15, 2010. Included in this bulletin: Regular Benefit

Pharmacological Management of Knee Pain

Pharmacological Management of Knee Pain Dr Indi Rasaratnam Consultant Rheumatologist, Epworth Health Care & The Alfred Senior Lecturer, Department of Medicine, Monash University Outline of Presentation

Non-operative Treatment of Osteoarthritis. Health Chat June 21 & 22, 2016 Aaron Leininger, MD

Non-operative Treatment of Osteoarthritis Health Chat June 21 & 22, 2016 Aaron Leininger, MD About Me Aaron Leininger, MD Clemson University Mechanical Engineering Varsity Soccer, Formula SAE race car

Patient History Form

Date of first appointment: / / MONTH DA Y YEAR Name: Address: LAST STREET CITY MARITAL STATUS: Never Married Spouse/Significant Alive/Age EDUCATION (circle highest level attended): Time of appointment:

Remicade (infliximab) DRUG.00002

Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous

Subject: Remicade (Page 1 of 5)

Subject: Remicade (Page 1 of 5) Objective: I. To ensure that Health Share/Tuality Health Alliance (THA) has a process by which the appropriate utilization of Remicade (Infliximab) for members whose diagnosis

RHEUMATOID ARTHRITIS DRUGS

Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra

ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION

UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine

Learning about Lupus. Learning About Lupus. Lupus Society of Illinois

Learning About Lupus Learning about Lupus Lupus Society of Illinois 525 W. Monroe Street, Suite 900 Chicago, Illinois 60661 Robert S. Katz, M.D. Professor of Medicine Rush University Medical Center Northwestern

Cimzia. Cimzia (certolizumab pegol) Description

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab

The Medical Letter. on Drugs and Therapeutics

The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

GET BACK TO YOUR FUTURE WITH SPECIALIZED SPINE CARE. A Guide for Patients

GET BACK TO YOUR FUTURE WITH SPECIALIZED SPINE CARE A Guide for Patients Your Spine Deserves Special Care Your spine is at the center of a delicately balanced system that controls all of your body s movements.

MUSCULOSKELETAL CONDITIONS

1. Medical Condition MUSCULOSKELETAL CONDITIONS Musculoskeletal conditions including those arising from injuries are common in sport. In this setting of sport, we traditionally classify injury according

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC

Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If

Rheumatoid arthritis

Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only

Perioperative Medicine:

Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents

Medical therapies and IBD

Medical therapies and IBD Although there is no cure for IBD, there are many treatment options available. There is no standard treatment for IBD that is effective in all situations or for all patients,